Emily Park, MD is a Principal at DCVC Bio, a life sciences venture capital fund based in San Francisco, focused on investments in therapeutic platforms and computational biology companies. Prior to joining DCVC Bio, she worked in the public markets as a biotech equities analyst at Point72 Asset Management and as a biotech equity research analyst at Goldman Sachs. Emily received a bachelor’s degree in English Literature from Columbia University and a Medical Degree from Rutgers New Jersey Medical School.